HBIO Harvard Bioscience Inc. Forecast, Technical & Fundamental Analysis
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing... Show more
HBIO is expected to report earnings to rise 92.86% to -27 cents per share on November 10
Q3'26
Est.
$-0.27
Q2'26
Beat
by $0.24
Q1'26
Missed
by $0.33
Q4'25
Missed
by $0.10
Q3'25
Missed
by $0.04
The last earnings report on August 11 showed earnings per share of -14 cents, beating the estimate of -37 cents. With 4.25K shares outstanding, the current market capitalization sits at 31.78M.
A.I. Advisor
published General Information
General Information
a manufacturer of apparatus and scientific instruments
A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.
HBIO in downward trend: price may drop because broke its higher Bollinger Band on August 18, 2026
HBIO broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 33 similar instances where the stock broke above the upper band. In of the 33 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for HBIO entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on HBIO as a result. In of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for HBIO just turned positive on August 03, 2026. Looking at past instances where HBIO's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
HBIO moved above its 50-day moving average on August 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for HBIO crossed bullishly above the 50-day moving average on August 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HBIO advanced for three days, in of 221 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.283) is normal, around the industry mean (4.976). P/E Ratio (0.000) is within average values for comparable stocks, (145.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.289). Dividend Yield (0.000) settles around the average of (0.017) among similar stocks. P/S Ratio (0.355) is also within normal values, averaging (72.056).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
